Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Mar;5(3):147-55.
doi: 10.1016/S1473-3099(05)01307-1.

Treatment and vaccines for severe acute respiratory syndrome

David A Groneberg  1 , Susan M Poutanen, Donald E Low, Hartmut Lode, Tobias Welte, Peter Zabel
Affiliations
Review

Treatment and vaccines for severe acute respiratory syndrome

David A Groneberg et al. Lancet Infect Dis. 2005 Mar.

Abstract

The causative agent of severe acute respiratory syndrome (SARS), which affected over 8000 individuals worldwide and was responsible for over 700 deaths in the 2002-2003 outbreak, is a coronavirus that was unknown before the outbreak. Although many different treatments were used during the outbreak, none were implemented in a controlled fashion. Thus, the optimal treatment for SARS is unknown. Since the outbreak, much work has been done testing new agents against SARS using in-vitro methods and animal models. In addition, global research efforts have focused on the development of vaccines against SARS. Efforts should be made to evaluate the most promising treatments and vaccines in controlled clinical trials, should another SARS outbreak occur.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Morphology of SARS coronavirus Electron microscopy reveals virus particles on the surface of infected cytopathic Vero E6 cells (A). The diameter of the virus particle ranges between 60 nm and 120 nm with a round to oval shape. Virions are also localised intracellularly within vesicles (B). Scale bars represent 100 nm. Reproduced with permission from Chin J Biochem Biophys 2003; 35: 587–91.
Figure 2
Figure 2
Structure of SARS coronavirus The SARS-coronavirus lipid bilayer consists of the membrane glycoprotein, the spike protein, and the envelope protein that surround the helical SARS-coronavirus nucleocapsid. The nucleocapsid consists of the nucleocapsid protein in association with viral RNA.
Figure 3
Figure 3
Treatment options A summary of the agents used clinically and studied experimentally regarding the pharmacological treatment and prevention of SARS
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Groneberg DA, Zhang L, Welte T, Zabel P, Chung KF. Severe acute respiratory syndrome: global initiatives for disease diagnosis. Q J Med. 2003;96:845–852. - PMC - PubMed
    1. Poon LL, Guan Y, Nicholls JM, Yuen KY, Peiris JS. The aetiology, origins, and diagnosis of severe acute respiratory syndrome. Lancet Infect Dis. 2004;4:663–671. - PMC - PubMed
    1. Reilley B, Van Herp M, Sermand D, Dentico N. SARS and Carlo Urbani. N Engl J Med. 2003;348:1951–1952. - PubMed
    1. World Health Organization (WHO) Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. 2003. http://www.who.int/csr/sars/country/table2004_04_21/en (accessed Feb 3, 2005)
    1. World Health Organization Multicentre Collaborative Network for Severe Acute Respiratory Syndrome Diagnosis A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. Lancet. 2003;361:1730–1733. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

-